( NYSE:ABT )

News from Abbott A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Apr 18, 2018, 07:45 ET Abbott Reports First-Quarter 2018 Results

Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2018. - First-quarter worldwide sales of $7.4...


Apr 17, 2018, 09:30 ET Abbott's New Ensure® Max Protein Helps Americans Go for Their #HealthGoals

Let's be honest – as adults, our busy schedules can get in the way of our own self-care, and that includes getting the right nutrition. The numbers...


Apr 11, 2018, 09:00 ET Abbott Initiates Groundbreaking Study to Assess Superiority of High-Resolution Imaging Versus Standard-of-Care Angiography in Treating Coronary Artery Disease

Abbott (NYSE: ABT) today announced the initiation of a clinical trial evaluating long-term outcomes of patients who undergo stent implantation...


Mar 29, 2018, 09:00 ET Abbott Initiates Trial to Evaluate Improved Survival And Outcomes with the CardioMEMS Monitor

Abbott (NYSE: ABT) announced today the company has initiated the landmark GUIDE-HF clinical trial using the CardioMEMS™ HF System. The GUIDE-HF...


Mar 21, 2018, 09:00 ET Abbott Hosts Conference Call for First-Quarter Earnings

Abbott (NYSE: ABT) will announce its first-quarter 2018 financial results on Wednesday, April 18, 2018, before the market opens. The...


Mar 19, 2018, 09:00 ET Abbott's MitraClip Therapy Receives National Reimbursement in Japan to Treat Patients with Mitral Regurgitation

Abbott (NYSE: ABT) today announced that the Ministry of Health Labour and Welfare (MHLW) in Japan granted national reimbursement for the company's...


Mar 11, 2018, 10:59 ET New Long-Term Data Show Improved Survival and Lower Rates of Stroke and Pump Thrombosis for Abbott's HeartMate 3 Heart Pump

Abbott (NYSE: ABT) announced new late-breaking clinical trial data from the MOMENTUM 3 clinical study, the largest left ventricular assist device...


Mar 01, 2018, 09:00 ET Abbott to Present at the Barclays Capital 2018 Global Healthcare Conference

Abbott (NYSE: ABT) will participate in the Barclays Capital Global Healthcare Conference on Wednesday, March 14, 2018. Brian Yoor, executive vice...


Feb 27, 2018, 09:00 ET Abbott and Surmodics Announce Agreement for Next-Generation Drug-Coated Balloon

Abbott (NYSE: ABT) and Surmodics (NASDAQ: SRDX) today announced that the companies have entered into an agreement whereby Abbott will have...


Feb 16, 2018, 11:20 ET Abbott Declares 377th Consecutive Quarterly Dividend

The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 28 cents per share. This marks the 377th consecutive...


Feb 07, 2018, 09:00 ET Abbott's App for FreeStyle® Libre System Now Available in Europe for Both iPhone™ and Android™

Abbott (NYSE: ABT) announced today the FreeStyle LibreLink app is now available in Europe for use with compatible smartphones2 (both iPhone and...


Jan 24, 2018, 07:45 ET Abbott Reports Fourth-Quarter 2017 Results

Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2017. - Fourth-quarter worldwide sales of $7.6...


Jan 04, 2018, 09:00 ET Abbott's Revolutionary Continuous Glucose Monitoring System, FreeStyle® Libre, Now Available To Medicare Patients

Abbott (NYSE: ABT) today announced that the FreeStyle® Libre System, the company's revolutionary new continuous glucose monitoring (CGM) system, is...


Jan 03, 2018, 09:00 ET New FDA MR-Conditional Labeling Approvals Further Expand Abbott's Portfolio of MRI-Ready Devices

Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for the Quadra...


Jan 02, 2018, 09:00 ET Abbott Launches Alinity™ h-series Integrated Hematology System, Combining Speed, Accuracy and Seamless Integration

Abbott (NYSE: ABT) today announced CE Mark for its Alinity h-series integrated system for hematology testing, joining the Alinity hq standalone...


Dec 18, 2017, 09:00 ET Abbott Hosts Conference Call for Fourth-Quarter Earnings

Abbott (NYSE: ABT) will announce its fourth-quarter 2017 financial results on Wednesday, Jan. 24, 2018, before the market opens. The...


Dec 15, 2017, 10:17 ET Abbott Raising Quarterly Dividend for 46th Straight Year

The board of directors of Abbott (NYSE: ABT) today increased the company's quarterly common dividend to 28 cents per share from 26.5 cents per...


Dec 04, 2017, 09:00 ET Abbott to Present at J.P. Morgan Healthcare Conference

Abbott (NYSE: ABT) will present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 8, 2018. Brian Yoor, executive vice president...


Nov 21, 2017, 08:00 ET Abbott apresenta LacLev®, primeira lactase mastigável no Brasil para intolerância à lactose

Para melhorar o conforto das pessoas intolerantes à lactose ao ingerir produtos lácteos, a Abbott, empresa global de cuidados para a saúde,...


Nov 06, 2017, 08:00 ET Abbott's MitraClip Approved as First Transcatheter Mitral Valve Repair Device in Japan

Abbott (NYSE: ABT) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved the company's MitraClip device for...


Oct 31, 2017, 09:00 ET Abbott Announces FDA Clearance for its Alinity™ ci-series Next-generation Diagnostic Systems

Abbott (NYSE: ABT) has secured U.S. Food and Drug Administration (FDA) 510(k) clearance for its Alinity™ ci-series instruments for clinical...


Oct 30, 2017, 13:20 ET Analysis of Landmark Study Showed Patients Treated for Left-Main Coronary Artery Disease with XIENCE Stent Felt Better Faster and Had Similar Long-Term Outcomes to Open-Heart Surgery

Abbott (NYSE: ABT) today announced that patients who underwent minimally-invasive implantation with a XIENCE coronary stent for left-main coronary...


Oct 30, 2017, 07:00 ET Abbott Introduces Next Generation of Most Widely Used Heart Stent for People with Coronary Artery Disease in Europe[1]

Abbott (NYSE: ABT) today announced it received CE Mark for XIENCE Sierra, the newest generation of the company's gold-standard XIENCE...


Oct 23, 2017, 09:00 ET Abbott Launches the First and Only Smartphone Compatible Insertable Cardiac Monitor in the U.S.

Abbott (NYSE: ABT) has secured U.S. Food and Drug Administration (FDA) clearance for the Confirm Rx™ Insertable Cardiac Monitor (ICM), the world's...


Oct 19, 2017, 14:59 ET A Great Place to Do Great Things: Developing Game-Changing Technology at Abbott

Science has spoken: Abbott (NYSE: ABT) is, again, among the best science-based companies to work for in the world. For the 14th year, the...